Literature DB >> 29576865

HCC with low- and normal-serum alpha-fetoprotein levels.

Brian I Carr1, Hikmet Akkiz2, Oguz Üsküdar2, Kendal Yalçın3, Vito Guerra4, Sedef Kuran2, Ümit Karaoğullarından2, Engin Altıntaş5, Ayşegül Özakyol6, Salih Tokmak2, Tuğsan Ballı2, Mehmet Yücesoy7, Halil İbrahim Bahçeci8, Abdulalh Ülkü2, Tolga Akçam2, Kamil Yalçın Polat9, Nazım Ekinci3, Halis Şimşek10, Necati Örmeci11, Abdulalh Sonsuz12, Mehmet Demir13, Murat Kılıç14, Ahmet Uygun15, Ali Demir16, Anıl Delik2, Burcu Arslan2, Figen Doran2, Sezai Yilmaz1,2,3,4,5,6,7,8,9,3,10,11,12,13,14,15,16,17,18, Yaman Tokat18.   

Abstract

A large database of 1773 HCC patients in Turkey was examined. 41.9% had alpha-fetoprotein (AFP) levels <20 IU/ml and an additional 16.123% had values between 20-100 IU/ml. This 58% of the cohort (<100 IU/ml AFP levels) was examined in detail. 66% of patients with small (<5 cm) HCCs had low AFP, compared to 49% of patients with larger (>5 cm) HCCs. The mean diameter (MTD) of larger MTD, low AFP tumors was 8.4cm. Therefore, factors other than AFP must contribute to HCC tumor growth. Larger tumors in low AFP patients had both higher platelet levels and increased PVT percent. Linear regression analysis for both MTD and multifocality showed that platelet numbers and presence of PVT were significant variables; whereas for PVT, significant variables were albumin, alkaline phosphatase and MTD. Comparisons between patients with AFP levels <20, 20-<100, 100-<1000 and >1000 IU/ml showed the most significant tumor finding was an increase in PVT percent between each group, and to a lesser extent, MTD. Thus, low- or normal-AFP HCCs constitute the majority of patients and have slightly lower MTD and much lower PVT percent than HCCs associated with elevated blood AFP levels. New, non-AFP markers are thus needed, especially for small HCCs.

Entities:  

Keywords:  AFP; HCC; MTD; PVT; Turkey

Year:  2018        PMID: 29576865      PMCID: PMC5865641          DOI: 10.4172/clinical-practice.1000393

Source DB:  PubMed          Journal:  Clin Pract (Lond)        ISSN: 2044-9038


  51 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

2.  A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI).

Authors:  David J Pinato; Justin Stebbing; Mitsuru Ishizuka; Shahid A Khan; Harpreet S Wasan; Bernard V North; Keiichi Kubota; Rohini Sharma
Journal:  J Hepatol       Date:  2012-06-23       Impact factor: 25.083

3.  Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.

Authors:  Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; H Yoshida; S Shiina; M Omata
Journal:  Cancer       Date:  2001-02-01       Impact factor: 6.860

4.  The low positive rate of serum alpha-fetoprotein levels in hepatitis C virus antibody-positive patients with hepatocellular carcinoma.

Authors:  J Furui; M Furukawa; T Kanematsu
Journal:  Hepatogastroenterology       Date:  1995 Sep-Oct

5.  A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Jessica A Davila; Jennifer Kramer; Peter Richardson
Journal:  Gastroenterology       Date:  2014-01-23       Impact factor: 22.682

6.  Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.

Authors:  Jong Young Choi; Seung Won Jung; Hee Yeon Kim; Myungshin Kim; Yonggoo Kim; Dong Goo Kim; Eun-Jee Oh
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

7.  Isolation, characterization and clinical evaluation of the gamma-glutamyltransferase associated with hepatocellular carcinoma.

Authors:  M Izumi
Journal:  Acta Med Okayama       Date:  1985-02       Impact factor: 0.892

8.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

Authors:  Taro Yamashita; Marshonna Forgues; Wei Wang; Jin Woo Kim; Qinghai Ye; Huliang Jia; Anuradha Budhu; Krista A Zanetti; Yidong Chen; Lun-Xiu Qin; Zhao-You Tang; Xin Wei Wang
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

9.  Low alpha-fetoprotein HCC and the role of GGTP.

Authors:  Brian I Carr; Vito Guerra; Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Gian Ludovico Rapaccini; Maria Di Marco; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Maria Chiaramonte; Franco Trevisani
Journal:  Int J Biol Markers       Date:  2014-12-09       Impact factor: 2.659

10.  TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.

Authors:  Liping Mao; Yueguo Wang; Delin Wang; Gang Han; Shouzhong Fu; Jianxin Wang
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240

View more
  18 in total

1.  Overexpression of Survivin-1, TAG-72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area.

Authors:  Andra-Iulia Suceveanu; Ioan Sergiu Micu; Gabriela-Izabela Baltatescu; Lucian Cristian Petcu; Nicolae Dobrin; Costel Brinzan; Cornelia Nitipir; Laura Mazilu; Florin Botea; Vlad Herlea; Felix Voinea; Adrian Paul Suceveanu
Journal:  Exp Ther Med       Date:  2021-01-26       Impact factor: 2.447

2.  Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken.

Authors:  Vaneet Jearth; Prachi S Patil; Shaesta Mehta; Sridhar Sundaram; Vishal Seth; Mahesh Goel; Shraddha Patkar; Munita Bal; Vidya Rao
Journal:  J Clin Exp Hepatol       Date:  2021-11-16

3.  Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients.

Authors:  Christina Jensen; Signe Holm Nielsen; Mohammed Eslam; Federica Genovese; Mette Juul Nielsen; Roslyn Vongsuvanh; Raj Uchila; David van der Poorten; Jacob George; Morten Asser Karsdal; Diana Julie Leeming; Nicholas Willumsen
Journal:  J Hepatocell Carcinoma       Date:  2020-11-09

4.  Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma.

Authors:  Hikmet Akkiz; Brian I Carr; Harika G Bag; Ümit Karaoğullarından; Kendal Yalçın; Nazim Ekin; Ayşegül Özakyol; Engin Altıntaş; Hatice Y Balaban; Halis Şimşek; Ahmet Uyanıkoğlu; Ayhan Balkan; Sedef Kuran; Oğuz Üsküdar; Yakup Ülger; Burak Güney; Anil Delik
Journal:  Int J Clin Pract       Date:  2020-12-12       Impact factor: 2.503

Review 5.  Proteomic approaches to investigate gammaherpesvirus biology and associated tumorigenesis.

Authors:  Danielle L Chappell; Maria C White; Blossom Damania
Journal:  Adv Virus Res       Date:  2020-11-09       Impact factor: 9.937

6.  Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma.

Authors:  Diana Julie Leeming; Signe Holm Nielsen; Roslyn Vongsuvanh; Pruthviraj Uchila; Mette Juul Nielsen; Alexander L Reese-Petersen; David van der Poorten; Mohammed Eslam; Detlef Schuppan; Morten Asser Karsdal; Jacob George
Journal:  Hepat Oncol       Date:  2020-12-18

7.  Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein.

Authors:  Young-Joo Jin; Habtamu Minassie Aycheh; Seonggyun Han; John Chamberlin; Jaehang Shin; Seyoun Byun; Younghee Lee
Journal:  BMC Med Genomics       Date:  2020-12-28       Impact factor: 3.063

8.  Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma.

Authors:  Omaima Mohamed Ali; Hussein Ahmed El Amin; Yousry Lotfy Sharkawy; Adnan Ahmed Mohamed Ali; Emad Farah Mohammed Kholef; Wael Abd Elgwad Elsewify
Journal:  Int J Gen Med       Date:  2020-05-18

9.  Mitotic quiescence in hepatic cancer stem cells: An incognito mode.

Authors:  Kandasamy Ashokachakkaravarthy; Biju Pottakkat
Journal:  Oncol Rev       Date:  2020-02-18

10.  Comment on experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis postdownstaging.

Authors:  Sami Akbulut; Tevfik Tolga Sahin
Journal:  Int J Surg Case Rep       Date:  2020-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.